BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hayes MW, Fung VS, Kimber TE, O'sullivan JD. Updates and advances in the treatment of Parkinson disease. Medical Journal of Australia 2019;211:277-83. [DOI: 10.5694/mja2.50224] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Luo S, Du L, Cui Y. Potential Therapeutic Applications and Developments of Exosomes in Parkinson’s Disease. Mol Pharmaceutics 2020;17:1447-57. [DOI: 10.1021/acs.molpharmaceut.0c00195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
2 Chen X, Wang Y, Wu H, Cheng C, Le W. Research advances on L-DOPA-induced dyskinesia: from animal models to human disease. Neurol Sci 2020;41:2055-65. [DOI: 10.1007/s10072-020-04333-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Islam MS, Azim F, Saju H, Zargaran A, Shirzad M, Kamal M, Fatema K, Rehman S, Azad MAM, Ebrahimi-Barough S. Pesticides and Parkinson's disease: Current and future perspective. J Chem Neuroanat 2021;115:101966. [PMID: 33991619 DOI: 10.1016/j.jchemneu.2021.101966] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kimber TE. Approach to the patient with early Parkinson disease: diagnosis and management. Intern Med J 2021;51:20-6. [DOI: 10.1111/imj.15148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yen K, Miyasaki JM, Waldron M, Yu L, Sankar T, Ba F. DBS-Edmonton App, a Tool to Manage Patient Expectations of DBS in Parkinson Disease. Neurol Clin Pract 2021;11:e308-16. [PMID: 34484906 DOI: 10.1212/CPJ.0000000000000962] [Reference Citation Analysis]
6 Mitchell SD, Sidiropoulos C. Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review. Toxins (Basel) 2021;13:226. [PMID: 33808714 DOI: 10.3390/toxins13030226] [Reference Citation Analysis]
7 Li X, Fan X, Yang H, Liu Y. Review of Metabolomics-Based Biomarker Research for Parkinson's Disease. Mol Neurobiol 2021. [PMID: 34826053 DOI: 10.1007/s12035-021-02657-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mathur S, Stamford J. Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Patient's Perspective. J Parkinsons Dis 2021. [PMID: 33967058 DOI: 10.3233/JPD-212650] [Reference Citation Analysis]
9 Gasiorowska A, Wydrych M, Drapich P, Zadrozny M, Steczkowska M, Niewiadomski W, Niewiadomska G. The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain. Front Aging Neurosci 2021;13:654931. [PMID: 34326765 DOI: 10.3389/fnagi.2021.654931] [Reference Citation Analysis]
10 Koponen M, Bell JS, Lalic S, Watson R, Koivisto AM, Ilomäki J. Treatment initiation for parkinson’s disease in Australia 2013–2018: a nation-wide study. BMC Geriatr 2022;22. [DOI: 10.1186/s12877-022-03095-3] [Reference Citation Analysis]
11 Zhang YT, He KJ, Zhang JB, Ma QH, Wang F, Liu CF. Advances in intranasal application of stem cells in the treatment of central nervous system diseases. Stem Cell Res Ther 2021;12:210. [PMID: 33762014 DOI: 10.1186/s13287-021-02274-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bitan G. The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question-are polyphenols a viable therapeutic option against proteinopathies? Ann Transl Med 2020;8:719. [PMID: 32617339 DOI: 10.21037/atm.2020.01.117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gonçalves VC, Cuenca-Bermejo L, Fernandez-Villalba E, Martin-Balbuena S, da Silva Fernandes MJ, Scorza CA, Herrero MT. Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson's Disease. Neuroscientist 2021;:1073858421990000. [PMID: 33583239 DOI: 10.1177/1073858421990000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Berlet R, Galang Cabantan DA, Gonzales-portillo D, Borlongan CV. Enriched Environment and Exercise Enhance Stem Cell Therapy for Stroke, Parkinson’s Disease, and Huntington’s Disease. Front Cell Dev Biol 2022;10:798826. [DOI: 10.3389/fcell.2022.798826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Riccardi C, Napolitano F, Montesarchio D, Sampaolo S, Melone MAB. Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics 2021;13:1897. [PMID: 34834311 DOI: 10.3390/pharmaceutics13111897] [Reference Citation Analysis]
16 Gazerani P. Probiotics for Parkinson's Disease. Int J Mol Sci 2019;20:E4121. [PMID: 31450864 DOI: 10.3390/ijms20174121] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
17 Gonzalez G, Hodoň J, Kazakova A, D'Acunto CW, Kaňovský P, Urban M, Strnad M. Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models. Eur J Med Chem 2021;213:113168. [PMID: 33508480 DOI: 10.1016/j.ejmech.2021.113168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]